1-3 of 3
David G. Roodman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease

Attaya Suvannasankha, Colin D. Crean, David Halladay, David G. Roodman, John Chirgwin
Journal: Blood
Blood (2022) 140 (Supplement 1): 7104–7105.
https://doi.org/10.1182/blood-2022-171069
Published: 2022
Journal Articles

A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma

Francesco Di Meo, Anjushree Iyer, Keith Akama, Christina Yu, Rujin Cheng, Annamaria Cesarano, Silvia Marino, Arafat Aljoufi, Rajesh Soni, Julie M Roda, James Sissons, Ly P Vu, Monica L. Guzman, Kun Huang, David G. Roodman, Fabiana Perna
Journal: Blood
Blood (2022) 140 (Supplement 1): 671–672.
https://doi.org/10.1182/blood-2022-167584
Published: 2022
Journal Articles

The CCR1 Antagonist BX470 Inhibits the Growth of Multiple Myeloma (MM) Cells That Produce MIP-1α.

Suzanne Lentzsch, MD, PhD, Gulsum Anderson, PhD, Li Cuiling, PhD, Horuk Richard, PhD, Markus Y. Mapara, MD, PhD, Ghobrial Irene, MD, David G. Roodman, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3383.
https://doi.org/10.1182/blood.V106.11.3383.3383
Published: 2005